The purpose of this platform study is to evaluate the safety, tolerability,pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitorscombined with Standard(s) of Care (SOC) or with each other.The first two subprotocols include the following:Subprotocol A: RMC-6291 + SOC Subprotocol B: RMC-6236 + SOC
The objective of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of novel RAS(ON) inhibitors in combination with standard(s) of care (SOC) or with each other. The first two sub-protocols include the following: Subprotocol A: RMC-6291 + SOC Subprotocol B: RMC-6236 + SOC
